share_log

6-K: Gsk's B7-H3-Targeted Antibody-Drug Conjugate, Gsk'227, Receives Ema Priority Medicines (Prime) Designation in Relapsed Extensive-Stage Small-Cell Lung Cancer

6-K: Gsk's B7-H3-Targeted Antibody-Drug Conjugate, Gsk'227, Receives Ema Priority Medicines (Prime) Designation in Relapsed Extensive-Stage Small-Cell Lung Cancer

6-K:Gsk的B7-H3靶向抗體藥物偶聯物Gsk'227獲得Ema優先藥物(Prime)稱號,用於治療複發性廣泛期小細胞肺癌
美股SEC公告 ·  12/16 09:08
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息